Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 6/20 | 0.47 |
| ▸ | KDR | P35968 | 8/20 | 0.45 |
| ▸ | FLT1 | P17948 | 2/20 | 0.45 |
| ▸ | AURKA | O14965 | 1/20 | 0.45 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.45 |
| ▸ | KIT | P10721 | 1/20 | 0.45 |
| ▸ | LRRK2 | Q5S007 | 6/20 | 0.41 |
| ▸ | MET | P08581 | 4/20 | 0.41 |
| ▸ | FLT4 | P35916 | 1/20 | 0.40 |
| ▸ | CSNK1D | P48730 | 2/20 | 0.38 |
| ▸ | CSNK1E | P49674 | 2/20 | 0.38 |
| ▸ | BRAF | P15056 | 1/20 | 0.37 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1258102 | 0.92 | KDR (0.46) | ABL1KDRFLT1AURKAPDGFRB | |
| SCHEMBL1260496 | 0.91 | KDR (0.49) | ABL1KDRFLT1AURKAPDGFRB | |
| SCHEMBL1259285 | 0.91 | KDR (0.45) | ABL1KDRFLT1AURKAPDGFRB | |
| SCHEMBL1258960 | 0.86 | KDR (0.53) | ABL1KDRFLT1AURKAPDGFRB | |
| Hydrochloric Acid SCHEMBL1260026 | 0.85 | KDR (0.53) | ABL1KDRFLT1AURKAPDGFRB | |
| SCHEMBL1259174 | 0.82 | KDR (0.48) | ABL1KDRFLT1AURKAPDGFRB | |
| SCHEMBL1260246 | 0.82 | KDR (0.51) | ABL1KDRFLT1AURKAPDGFRB | |
| SCHEMBL1258121 | 0.76 | KDR (0.55) | ABL1KDRFLT1AURKAPDGFRB | |
| SCHEMBL1259283 | 0.75 | KDR (0.58) | ABL1KDRFLT1AURKAPDGFRB | |
| SCHEMBL1258100 | 0.74 | KDR (0.53) | ABL1KDRFLT1AURKAPDGFRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8445509-B2 | Fused heterocyclic derivatives and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-05-21 | — | — | US | disclosed |
| US-20110046169-A1 | FUSED HETEROCYCLIC DERIVATIVES AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-02-24 | — | — | US | disclosed |
| WO-2009136663-A1 | FUSED HETEROCYCLIC DERIVATIVES AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-11-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110046169-A1 | FUSED HETEROCYCLIC DERIVATIVES AND USE THEREOF | ABL1, MAP4K2, MAP3K20 | ABL1 1/4885KDR 966/4885FLT1 1499/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.